Search Within

Steven M Sugarman

Formats
  1. Meeting Abstract (23)
  2. Journal Article (16)
Groups
  1. Breast Medicine Service (39)
  2. Department of Medicine (39)
  3. Solid Tumor Oncology Division (39)
  4. Survivorship Research (39)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (32)
  6. Epidemiology and Biostatistics (27)

More Groups

People
  1. Clifford Hudis (37)
  2. Larry Norton (29)
  3. Chau Dang (23)
  4. Gabriella D'Andrea-Carlino (20)
  5. Diana Lake (17)
  6. Sujata Patil (17)

More People

Years
  1. 2021 (1)
  2. 2017 (3)
  3. 2016 (3)
  4. 2015 (3)
  5. 2014 (2)
  6. 2011 (4)

More Years

Publications
  1. Breast Cancer Research and Treatment (11)
  2. Journal of Clinical Oncology (10)
  3. Cancer Research (7)
  4. Clinical Breast Cancer (4)
  5. Clinical Cancer Research (3)
  6. Annals of Oncology (1)

More Publications

Publishers
  1. Springer (11)
  2. American Association for Cancer Research (10)
  3. American Society of Clinical Oncology (10)
  4. Elsevier Inc. (5)
  5. Oxford University Press (2)
  6. Pergamon-Elsevier Science Ltd (1)

Results (39)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Adjuvant dose-dense doxorubicin-cyclophosphamide x 4 with or without bevacizumab is safe: No evidence of short-term changes in left ventricular ejection fraction
    Meeting Abstract

    Morris, P. G.; Dickler, M.; Mcarthur, H.; Traina, T.; Godfrey, L.; Steingart, R.; Rugo, H.; Lin, N.; Moy, B.; Come, S.; more...
    Cancer Research (2009)

    Fulltext@MSK | Save
  • Cardiac safety of adjuvant bevacizumab (B) plus dose-dense doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel (nab-P) in patients with early stage breast cancer
    Meeting Abstract

    Mcarthur, H.; Rugo, H.; Nulsen, B.; Traina, T.; Patil, S.; Zhou, Q.; Steingart, R.; Dang, C.; Park, J.; Moasser, M.; more...
    Cancer Research (2009)

    Fulltext@MSK | Save
  • Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: Updated results
    Meeting Abstract

    Dang, C.; Lin, N.; Moy, B.; Come, S.; Lake, D.; Theodoulou, M.; Troso-Sandoval, T.; Dickler, M.; Gorsky, M.; D'Andrea, G.; more...
    Cancer Research (2009)

    Fulltext@MSK | Save
  • A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma
    Journal Article

    Sugarman, S.; Wasserheit, C.; Hodgman, E.; Coglianese, M.; D'alessandro, A.; Fornier, M.; Troso-Sandoval, T.; D'Andrea, G.; Drullinsky, P.; Lake, D.; more...
    Breast Cancer Research and Treatment (2009)

    Fulltext@MSK | Save
  • Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC)
    Meeting Abstract

    Modi, S.; Sugarman, S.; Stopeck, A.; Linden, H.; Ma, W.; Kersey, K.; Johnson, R. G.; Rosen, N.; Hannah, A. L.; Hudis, C. A.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Nanoparticle albumin-bound paclitaxel in 3 dosing schedules with bevacizumab as first line therapy for HER2-negative metastatic breast cancer: An interim safety analysis
    Meeting Abstract

    Seidman, A. D.; Conlin, A. K.; Moynahan, M. E.; Bach, A.; Troso-Sandoval, T.; Sugarman, S.; Forero, A.; Kerr, R.; Wright, G.; Hudis, C. A.
    EJC Supplements (2008)

    Fulltext@MSK | Save
  • Tanespimycin (17-allylamino-17-demethoxy-geldanamycin; 17-AAG) in breast cancer
    Meeting Abstract

    Modi, S.; Sugarman, S.; Stopeck, A.; Linden, H.; Ma, W.; Chandarlapaty, S.; Solit, D.; Norton, L.; Rosen, N.; Kersey, K.; more...
    Annals of Oncology (2008)

    Fulltext@MSK | Save
  • The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer
    Journal Article

    Dang, C.; Fornier, M.; Sugarman, S.; Troso-Sandoval, T.; Lake, D.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Dickler, M.; Currie, V.; more...
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible
    Journal Article

    Dang, C.; D'Andrea, G.; Lake, D.; Sugarman, S.; Fornier, M.; Moynahan, M. E.; Gilewski, T.; Hurria, A.; Mills, N.; Troso-Sandoval, T.; more...
    Clinical Breast Cancer (2008)

    Fulltext@MSK | Save
  • Adjuvant (adj) bevacizumab (B) plus dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel (nab-p) in early stage breast cancer (BC) patients (pts): Cardiac safety
    Meeting Abstract

    Dickler, M. N.; Traina, T.; Panageas, K.; Steingart, R.; Dang, C.; Fornier, M.; Sugarman, S.; Norton, L.; Hudis, C.; Rugo, H.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save